BOSTON, MA, UNITED STATES, January 13, 2026 /EINPresswire.com/ -- During JPM Week 2026, Hill Research released a new ...

PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, is pleased to announce the ...

As of Friday, January 23, Molecular Partners AG’s MOLN share price has surged by 6.99%, which has investors questioning if ...

Paris, France and Munich, Germany, 20 January 2026 – TRiCares SAS (“TRiCares”), a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, today announces it has ...

South Africa faces the reality of serious skills shortages in healthcare. There are many reasons, which need no repetition here. What needs more attention is the parallel reality unfolding quietly ...

The first patients have been dosed in LTR Pharma’s Phase II pharmacokinetic clinical study of SPONTAN, its nasal spray to ...

Introduction Maternal and child mortality has markedly decreased worldwide over the past few decades. Despite this success, the decline remains unequal across countries and is overall insufficient to ...

Walmart this spring will roll out clinical research sites in a limited number of stores and former shuttered clinic sites in ...

A spending bill would ensure the financial future of the Health Program, but the measure must still pass the U.S. Senate.

Ossium Health will present new clinical data from its ongoing PRESERVE I study at the 2026 Tandem Meetings on February 4-7, 2026 in Salt Lake City.

OS Animal Health (OSAH), a wholly owned OS Therapies (OSTX) subsidiary, targets an IPO on NYSE American or Nasdaq ...

"This research represents a pivotal step in understanding how the immune system responds to vaccines through the use of real-world data collected remotely," said Praduman "PJ" Jain, CEO, Vibrent ...